Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase I-II Study of Safety and Activity of Low Dose Interleukin-2
Phase of Trial: Phase II
Latest Information Update: 28 Apr 2017
Price : $35 *
At a glance
- Drugs Aldesleukin (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Pharmacodynamics
- Acronyms IMODALS
- 31 Aug 2018 Biomarkers information updated
- 28 Apr 2017 Primary endpoint (CD4+ CD25+ CD127- FoxP3+(Treg) cells: change in percentage of total lymphocytes) has been met.
- 28 Apr 2017 Primary endpoint (Cell count (CD4+ CD25+ CD127- FoxP3+(Treg) cells: change in number) has been met.